• 1. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 2. Aluminium alkyl and aryloxide complexes of pyrazine and bipyridines: synthesis and structure?
  Doug Ogrin,Laura H. van Poppel,Simon G. Bott,Andrew R. Barron Dalton Trans., 2004, 3689-3694
• 3. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 4. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 5. An aptasensor for the detection of ampicillin in milk using a personal glucose meter
  Xixi Li,Nanwei Zhu,Ruohan Li,Qinpu Zhang Anal. Methods, 2020,12, 3376-3381

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylmethylamines

Introduction to (2,4-Difluorophenyl)methyl(propyl)amine (CAS No. 637015-27-1)

(2,4-Difluorophenyl)methyl(propyl)amine (CAS No. 637015-27-1) is a synthetic organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, including a difluorophenyl group and a propylamine moiety, which contribute to its potential biological activities and applications.

The chemical structure of (2,4-difluorophenyl)methyl(propyl)amine consists of a benzene ring substituted with two fluorine atoms at the 2 and 4 positions, a methyl group, and a propylamine chain. The presence of the difluorophenyl group imparts specific electronic and steric properties to the molecule, which can influence its interactions with biological targets. The propylamine moiety, on the other hand, provides additional functional groups that can participate in hydrogen bonding and other non-covalent interactions.

Recent studies have explored the potential of (2,4-difluorophenyl)methyl(propyl)amine in various therapeutic areas. One notable area of research is its role as a ligand for G protein-coupled receptors (GPCRs), which are important targets for many drugs. GPCRs are involved in a wide range of physiological processes, including neurotransmission, hormone signaling, and immune responses. The ability of (2,4-difluorophenyl)methyl(propyl)amine to modulate GPCR activity makes it a promising candidate for the development of new therapeutic agents.

In addition to its potential as a GPCR ligand, (2,4-difluorophenyl)methyl(propyl)amine has also been investigated for its anti-inflammatory properties. Inflammation is a complex biological response to harmful stimuli and is associated with various diseases such as arthritis, asthma, and inflammatory bowel disease. Preclinical studies have shown that (2,4-difluorophenyl)methyl(propyl)amine can inhibit the production of pro-inflammatory cytokines and reduce inflammation in animal models. These findings suggest that this compound may have therapeutic potential in the treatment of inflammatory disorders.

The pharmacokinetic properties of (2,4-difluorophenyl)methyl(propyl)amine have also been studied to assess its suitability as a drug candidate. Pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) are crucial for determining the bioavailability and safety profile of a compound. Research has indicated that (2,4-difluorophenyl)methyl(propyl)amine exhibits favorable ADME properties, with good oral bioavailability and low toxicity in preclinical models.

The safety profile of (2,4-difluorophenyl)methyl(propyl)amine has been evaluated through various toxicological studies. These studies have shown that the compound is generally well-tolerated at therapeutic doses and does not exhibit significant adverse effects. However, further research is needed to fully understand its long-term safety and potential side effects.

In conclusion, (2,4-difluorophenyl)methyl(propyl)amine (CAS No. 637015-27-1) is a promising compound with potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and biological activities make it an attractive candidate for further development as a therapeutic agent. Ongoing research continues to explore its mechanisms of action and potential therapeutic uses in various disease conditions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)